Phase 4 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People who are willing and able to provide written consent before any study procedures begin
- People whose general health and ability to carry out daily activities meets a certain minimum standard (known as ECOG performance status of 2 or below — confirm with trial site)
- People who have been diagnosed through a tissue biopsy with a locally advanced or spreading (metastatic) gastroenteropancreatic neuroendocrine tumour (GEP NET) that is low-to-intermediate grade (Grade 1 or 2), well-developed in structure, and not producing excess hormones
- People whose scans show the disease has continued to grow or spread while receiving a standard first-line medication called a somatostatin analogue (SSA), at the approved dose or higher
- For the targeted therapy part of the trial: people for whom a doctor has determined that treatment with either sunitinib or everolimus is appropriate as a second treatment
- For the PRRT part of the trial: people for whom a doctor has determined that a type of radiation therapy called PRRT (using a medicine called Lutetium-177 oxodotreotide) is appropriate as a second treatment
Who may not be able to join:
- People for whom chemotherapy is the recommended next treatment for their GEP NET
- People whose tumour is poorly formed (poorly differentiated), is Grade 3, or is growing very rapidly
- People who have previously been treated with everolimus, sunitinib, or PRRT
- People who have a medical reason not to use SSA medication, a known allergy to it, or whose only reason for using SSA would be to control hormone-related symptoms
- People whose disease was progressing while taking a lower-than-approved dose of their SSA medication
- People whose tumour is actively producing hormones and causing related symptoms (known as a functional NET)
- People currently receiving treatment for another cancer
- People currently taking part in another clinical trial involving an anti-cancer treatment
- People who have any health findings, mental health conditions, or other medical issues that, in the opinion of the investigator, could affect their safety or the quality of the study data
- People who are pregnant or breastfeeding at the time of screening, or who plan to become pregnant during the treatment phase of the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Marc Peeters, MD, University Hospital, Antwerp
Phone: 03821
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
the difference in progression-free survival (PFS) in patients continuing or stopping second-line therapy with SSAs, as assessed by the blinded local investigator on cross-sectional imaging, according to RECIST 1.1 criteria per substudy; The difference in time to deterioration (TTD) in patients continuing or stopping second-line therapy with SSAs per substudy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.